Millennium Pharmaceuticals Limited

Zymeworks Inc.

Amgen Fremont Inc.

Other

Abbott Laboratories Corporation

Amgen Inc.

Zymeworks Bc Inc.

Var2 Pharmaceuticals Aps

Amgen British Columbia Inc.

Medimmune Limited

Takeda Pharmaceutical Company Limited

The University of British Columbia

Abgenix, Inc.

Centre for Drug Research and Development

John Stephen Babcook

Bradley John Hedberg

Jaspal Singh Kang

James R Rich

Geoffrey C Winters

Alexander Laurence Mandel

Tom Han Hsiao Hsieh

Larry L Green

Ole Petter Veiby

Elyse Marie Josée Bourque

Orit Foord

Xiao-Chi Jia

Palaniswami Rathanaswami

Michael R Hughes

Calvin D Roskelley

Jan Peter Bergqvist

Ian Nevin Foltz

Mary Haak-Frendscho

Tariq Ghayur

Boris Labkovsky

Meina Liang

Theresa O'Keefe

Shixin Qin

Xiao Feng

Qiaojuan Jane Su

Christopher John Bond

Edward Alvin Greenfield

Scott L Klakamp

Giorgio Senaldi

Jeffrey W Voss

Kathy Manchulenko

Raffaella Faggioni

Yen-Wah Lee

Mads Daugaard

Kelly Marshall McNagny

James Wieler

Diana Canals Hernaez

Klas Ola Blixt

Ismael Samudio

Katherine Grace MacDonald

Anna Von Rossum

Pamela Megan Dean

Samuel S Nam

Brad Hedberg

Craig Pigott

Ali El-Salanti

Theresa O'keefe

Li Zhang

Chadwick Terence King

Scott A Hammond

Xiao-Dong Yang

Stuart Daniel Barnscher

Bellur S Prabhakar

Michelle Morrow

Melanie Boyle

Matthieu Chodorge

Ross Anthony Stewart

Laura Sekirov

Marat Alimzhanov

Christophe Queva

Kathleen Ann Mulgrew

Madeleine Dahlback

Varghese Palathumpat

Kelley Marshall Mcnagny

Kimberly Ashely Snyder

Melissa Coughlin

Elyse Marie Bourque

Rozanne Lee

Scott Klakamp

Meina L Liang

Tom Han Hsieh

Tom Han Hsiao Hsie

Alexander L Mandel

Kathy Manchulencho

Quiaojuan Jane Su

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Cytotoxic and anti-mitotic compounds, and methods of using the same

The present invention is directed to anti-podocalyxin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of cancer.

Anti-podocalyxin antibodies and methods of using the same

The present invention is directed to compositions of matter useful for the treatment of cancer in mammals and to methods of using those compositions of matter for the same. Antibodies specific for podocalyxin designated Ab1 and 3G2 are disclosed, as is the use of said antibodies for the inhibition of growth of a tumor that expresses podocalyxin, and the use of said anti bodies for targeting tumour endothelial cells that express podocalyxin.

The present disclosure provides light chain polypeptides that include a C-terminal extension, as well as antibodies and antibody conjugates containing such modified light chain polypeptides, where the C-terminal extension includes one or more cysteine residues. Conjugates that include an antibody of the present disclosure conjugated to an agent via the cysteine residue of the C-terminal amino acid extension are also provided. The present disclosure further provides nucleic acids encoding an antibody light chain polypeptide that includes a C-terminal amino acid extension including a cysteine residue. Pharmaceutical compositions including the antibodies or conjugates of the present disclosure are also provided, as are methods of making and use of the modified anti-bodies and conjugates of the present disclosure.

Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof

Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Anti-GCC antibody molecules and related compositions and methods

VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.

VAR2CSA-drug conjugates

VAR2CSA-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum drug-resistant cancers. VAR2CSA-drug conjugates (VDCs) comprise a VAR2CSA polypeptide that is capable of binding to oncofetal chondroitin sulfate (ofCS) and one or more toxins having anti-cancer activity conjugated to the VAR2CSA polypeptide, either directly or via a linker.

Compositions and methods for the treatment of platinum-drug resistant cancer

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Antibodies that bind OV064 and methods of use therefor

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having structure (I).

Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.

Targeted binding agents against B7-H1

Growing community of inventors

Vancouver, Canada

John Stephen Babcook